Making cancer clinical trials SMMART

OHSU is giving cancer researchers an unprecedented ability to test drug combinations selected to overwhelm tumors’ ability to adapt

By Joe Rojas-Burke November 16, 2018 Portland, Oregon

Downloads

Gordon Mills, M.D., Ph.D.

Gordon Mills, M.D., Ph.D., director of precision oncology for the OHSU Knight Cancer Institute and a professor in the OHSU School of Medicine. (OHSU/Kristyna Wentz-Graff)

Joe Gray, Ph.D.

Joe Gray, Ph.D., associate director for Biophysical Oncology, OHSU Knight Cancer Institute. (OHSU)

Zahi Mitri, M.D.

Zahi Mitri, M.D., an assistant professor of medicine (hematology and medical oncology), in the OHSU School of Medicine. (OHSU/Fritz Liedtke)

Raymond Bergan, M.D.

Raymond Bergan, M.D., Division Chief of Hematology and Medical Oncology and professor of medicine at OHSU. (OHSU/Kristyna Wentz-Graff)

Knight Cancer Institute researchers

Zahi Mitri, M.D., (left) talks with Gordon Mills, M.D., Ph.D., at the Knight Cancer Research Center in Portland, September 13, 2018. (OHSU/John Valls)

Gordon Mills, M.D., Ph.D.

Gordon Mills, M.D., Ph.D., at the Knight Cancer Research Center in Portland, September 13, 2018. (OHSU/John Valls)

Christopher Corless, M.D., Ph.D.

Executive director and chief medical officer, Knight Diagnostic Laboratories, OHSU Knight Cancer Institute; Professor of pathology, OHSU School of Medicine. (OHSU)